ArticleJAMA network open2025
Polygenic Risk, Agent Orange Exposure, and Lymphoid Neoplasms in the Veterans Affairs Million Veteran Program.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Chronic lymphocytic leukemia associated with genetic susceptibility and occupational glyphosate exposure: a case report.Frontiers in oncology · 2026Article
- Error in Figure.JAMA network open · 2025Article
Corrections and comments
- Erratum issuedError in Figure.2025
Authors and funding
6 authors.
Funding
Abstract
Importance: Agent Orange (AO), a toxic herbicide mixture contaminated with carcinogenic dioxin, was widely used during the Vietnam War. Although epidemiologic evidence suggests AO exposure is associated with increased lymphoid malignant neoplasm risk, the details of this association and its potential interaction with genetic factors remain unclear. Objective: To evaluate (1) whether AO exposure was associated with increased risk of lymphoid malignant neoplasms, (2) associations of polygenic risk scores (PRSs) in specific lymphoid malignant neoplasms, and (3) whether there was a genetic component × exposure interaction associated with increased risk of developing lymphoid malignant neoplasms. Design, Setting, and Participants: A case-control study of 255 155 US veterans enrolled in the Veterans Affairs Million Veteran Program was conducted with available genotype, AO exposure information, and lymphoid malignant neoplasm diagnosis from January 1, 1965, through June 11, 2024. Exposures: AO exposure status (based on self-reported survey) and PRS derived from genome-wide association studies of lymphoid malignant neoplasms. Main Outcomes and Measures: Risk of developing lymphoid malignant neoplasm subtypes: chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and multiple myeloma. Results: A total of 255 155 non-Hispanic White veterans (median [IQR] age, 67 [61-74] years; 235 895 [92.5%] male) with both PRS and AO data were included in this study. AO exposure was associated with an increased risk of chronic lymphocytic leukemia (odds ratio [OR], 1.61; 95% CI, 1.40-1.84), diffuse large B-cell lymphoma (OR, 1.26; 95% CI, 1.03-1.53), follicular lymphoma (OR, 1.71; 95% CI, 1.39-2.11), and multiple myeloma (OR, 1.58; 95% CI, 1.35-1.86). Similarly, PRS was associated with all subtypes: chronic lymphocytic leukemia (OR, 1.81; 95% CI, 1.70-1.93), diffuse large B-cell lymphoma (OR, 1.12; 95% CI, 1.02-1.21), follicular lymphoma (OR, 1.33; 95% CI, 1.21-1.47), marginal zone lymphoma (OR, 1.17; 95% CI, 1.04-1.32), and multiple myeloma (OR, 1.41; 95% CI, 1.31-1.52). No significant PRS × AO interactions were observed. Conclusions and Relevance: To date, this is the largest case-control study of AO exposure and risk of lymphoid malignant neoplasm subtypes and the only study to investigate an AO × gene association with risk. The study found independent associations of both genetic predisposition and AO exposure on several lymphoid malignant neoplasm subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.